Clinical trials
Glioma clinical trials
Below are recruiting glioma clinical trials, each written for real people, not researchers. We’re tracking 339 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05096481RecruitingPhase 2
Vaccine trial for children with certain brain tumors
This Phase 2 study tests a vaccine made to target CMV (a virus) in order to treat children with medulloblastoma or newly diagnosed high-grade glioma/DIPG. If you’re eligible, you’d receive the study vaccine and the team would closely watch how well it’s tolerated and how your cancer responds.
Aurora, ColoradoAges 3–39 - NCT05180825RecruitingPhase 2
Tested a targeted drug plus fewer cancers treatments for children
This Phase 2 trial studies whether a targeted medicine that blocks MEK can work better than chemotherapy for certain slow-growing brain tumors in children. You may qualify if your tumor has specific genetic features and has not already been treated with non-surgery therapies.
AmiensAges 1 month–25 years - NCT05188508RecruitingPhase 2
Pembrolizumab, olaparib, and temozolomide for recurrent glioma
This trial studies whether combining three medicines can slow or shrink recurrent glioma (a type of brain tumor). It is for adults whose tumor has come back after standard treatment, with certain genetic tumor markers that may help guide whether you can join.
Hartford, ConnecticutAges 18 years+ - NCT05259605Recruiting
Study uses brain tumor tissue and scans to track treatment outcomes
This is an observational study that collects and compares information from patients with primary brain tumors and their treatment results. It uses stored tumor tissue and brain scans to better understand outcomes using updated tumor classification methods.
InnsbruckAges 18 years+ - NCT05310448Recruiting
Using a scalp device plus temozolomide for brainstem gliomas
This study tests whether Tumor Treating Fields (a wearable electrical device placed on the scalp) combined with temozolomide can treat brainstem gliomas (tumors in key parts of the brainstem). It may help slow tumor growth and improve outcomes for adults who have already finished surgery/radiation or are otherwise ready for the next treatment step.
Atlanta, GeorgiaAges 18 years+ - NCT05345002RecruitingPhase 2
ATRA plus PD-1 therapy for IDH-mutant recurrent brain tumors
This trial studies whether adding all-trans retinoic acid (ATRA) to an anti–PD-1 immune therapy can slow recurrent or worsening IDH-mutant glioma. It may help by boosting the immune system’s attack on the tumor.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05474573Recruiting
Laser-guided removal of brain tumors using special light
This study tests a method to help surgeons find and remove brain tumors that show up on MRI with contrast dye (often high-grade gliomas and brain metastases). If you newly have one of these tumors, the trial may help improve how completely tumors can be removed while protecting important brain areas.
MoscowAges 18–79 - NCT05489783Recruiting
Study board for adults with NF1 and glioma
This study collects and reviews past and future health records for adults who have both neurofibromatosis type 1 (NF1) and a brain tumor called glioma. The goal is to better understand these conditions and how they progress, which can help guide future research and care.
Basking Ridge, New JerseyAges 18 years+ - NCT05532397Recruiting
Tested lab-chosen drug combo for recurrent brain tumor
This study uses a patient’s tumor tissue to test drug combinations in the lab, aiming to help choose a better second-line treatment for recurrent high-grade astrocytic glioma. If your tumor tissue can be tested, the results may guide a more personalized medication plan.
SingaporeAges 21–99 - NCT05565118RecruitingPhase 1
Brain activity study during surgery for high-grade glioma
This early-stage study measures electrical brain activity during brain tumor surgery to see if it can predict tumor return or progression. You may be offered the additional measurements while your surgeon removes a suspected or known high-grade glioma.
Cleveland, OhioAges 18 years+ - NCT05580562RecruitingPhase 3
ONC201 for newly diagnosed H3 K27M brain tumor after radiation
This study tests whether ONC201 (also called ONC201) can improve outcomes for people with a newly diagnosed H3 K27M–mutant diffuse brain tumor after they finish radiation. It looks for safety and whether treatment can help control the tumor.
Phoenix, ArizonaAges Any age - NCT05609994RecruitingPhase 1
Vorasidenib plus a peptide vaccine for recurrent low-grade glioma
This Phase 1 study tests vorasidenib combined with a personalized tumor-targeting peptide vaccine in adults with a specific type of recurrent brain tumor. It aims to see how safe the combination is and whether it can help slow the tumor’s growth.
Durham, North CarolinaAges 18 years+ - NCT05632562RecruitingEarly Phase 1
PET/MRI scan study for newly diagnosed brain cancer changes
This early-phase study uses special PET/MRI scans to look at how a newly diagnosed high-grade glioma is changing under standard treatment. The goal is to see whether these scans can better assess the disease, which may help guide future care.
Birmingham, AlabamaAges 10–89 - NCT05660369RecruitingPhase 1
CAR T-cell treatment for EGFR-mutant glioblastoma
This Phase 1 trial tests a new immune treatment made from your own immune cells to attack glioblastoma (a brain tumor), especially tumors with a specific EGFR change called EGFRvIII. It mainly focuses on safety and early signs of effectiveness, and some participants will also need surgery/biopsy and an implanted port for the treatment.
Boston, MassachusettsAges 18 years+ - NCT05686798RecruitingPhase 1
Gene therapy plus radiation for recurring brain tumor
This early-phase study tests a “suicide gene” therapy delivered by a virus along with radiation for adults whose high-grade brain tumor has come back or grown again. The goal is to see if the treatment is safe and can help control the tumor.
Detroit, MichiganAges 18 years+ - NCT05698524RecruitingPhase 1
Temodar plus an investigational pill for recurrent brain cancer
This Phase 1 study tests an investigational drug (PCI-24781) together with Temodar in people whose high-grade glioma (grade III/IV) has come back after prior treatment. It aims to find a safe dose and see how well the combination may work for recurrent disease.
Omaha, NebraskaAges 19 years+ - NCT05717712RecruitingPhase 1
Study virus treatment for newly diagnosed DIPG in children
This Phase 1 trial tests a type of cancer-fighting virus given directly into the tumor for children with newly diagnosed diffuse intrinsic pontine glioma (DIPG). The goal is to see if it can be delivered safely and to learn how the body responds to it.
Beijing, Beijing MunicipalityAges 1–18 - NCT05717699RecruitingPhase 1
Trial of a virus treatment for DIPG in children
This Phase 1 trial tests a lab-made cancer virus (Ad-TD-nsIL12) in children with DIPG whose tumor keeps growing after standard treatment. It mainly focuses on safety and how the treatment works, and it may help shrink or control the tumor by stimulating the immune system.
Beijing, Beijing MunicipalityAges 1–18 - NCT05762419RecruitingPhase 1
FUS and etoposide treatment for midline brain tumors
This early-phase study tests whether focusing ultrasound (FUS) plus etoposide can help treat children and teens with diffuse midline glioma that affects the brainstem (pons) and/or thalamus, especially with an H3K27M change. Participants must have cancer that is getting worse and be healthy enough to safely receive study treatment.
New York, New YorkAges 4–21 - NCT05804227RecruitingEarly Phase 1
Ulixertinib for glioma driven by MAPK pathway
This early-phase trial tests ulixertinib (a targeted pill) to see how well it works for certain gliomas driven by the MAPK/RAF-MEK-ERK signaling pathway. It also looks at whether the drug can help control tumor growth around the time of treatment planning.
Houston, TexasAges 18 years+ - NCT05954858Recruiting
Surgical flap to help treat glioblastoma by bypassing the blood-brain barrier
This trial tests a surgical technique that places a tissue flap near a glioblastoma surgery site to help medicines reach the brain more effectively. You might be considered if you are planning major brain tumor surgery and meet specific health, imaging, and lab requirements.
New York, New YorkAges 18 years+ - NCT05990244Recruiting
MRE scan to measure brain tumor stiffness before surgery
This study uses a special MRI called magnetic resonance elastography (MRE) to measure how stiff a brain tumor (glioma) is and how well it sticks to nearby brain tissue. The goal is to help doctors better prepare for surgery by knowing these details beforehand.
Shenyang, LiaoningAges 18–80 - NCT06002711Recruiting
Predicting brain tumor genetics with MRI
This study uses MRI scans to predict key genetic markers and outcomes in people with high-grade gliomas (aggressive brain tumors). If you are between 18 and 70 years old and have been diagnosed or are suspected of having a high-grade glioma, this research may help better understand your tumor without extra procedures.
Shanghai, Select A State Or ProvinceAges 18–70 - NCT06011109RecruitingPhase 1/Phase 2
APG-157 plus Avastin for recurrent high-grade glioma
This trial tests a combination of two drugs—APG-157 (an oral plant-based medicine) and bevacizumab (Avastin)—for people with recurrent high-grade brain tumors that have already been treated with standard therapies. The goal is to see if adding APG-157 can help control the tumor better.
Rochester, MinnesotaAges 19 years+
Hear when a new Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for glioma?
- Yes. Clin2 currently lists 339 recruiting glioma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a glioma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a glioma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.